Toxicology and applied pharmacologyHumansGefitinibLung NeoplasmsAntineoplastic AgentsCell Line
An intestinal matrix-based human lung cancer model reflects clinical data from gefitinib on dosage-dependent efficacy.
Elena Johanna Weigl, Thorsten Walles, Sarah Nietzer, Gudrun Dandekar, Heike Walles, Claudia Goettlich
Published: 202610.1016/j.taap.2025.117625
Abstract
Lung cancer is the leading cause for cancer related death worldwide. One treatment option for patients with pulmonary adenocarcinoma is the targeted therapy gefitinib (Iressa®, ZD1839). As with other promising targeted therapies, desired in vivo effe…
Preview only. Read the full abstract at the source